AnaptysBio IncANAB
Price$50.26

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $232.4M+154.6% YoYTTM through 31 Mar 2026
Net Income -$26.8MTTM through 31 Mar 2026
Free Cash Flow $4.4MTTM through 31 Mar 2026

Margins

Current
Gross Margin97.6%
EBITDA Margin17.8%
Operating Margin-135.5%
Net Margin-11.5%

Returns

-210.1%ROE
-8.1%ROA
-64.3%ROIC

Balance Sheet Health

Debt / Equity21.76x
Current Ratio7.58x
Net Debt-$9.1Mnet cash position
Cash & Equivalents$248.5M

Quality Metrics

Altman Z-Score1.63
Piotroski F-Score5 / 9
FCF Margin1.9%
Earnings-Beat Rate100.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $234.6M
Diluted EPS-$1.02TTM
'19'20'21'22'23'24'25
FY2025: $-0.46

Dividend

No dividend

Capital Allocation

Capex Intensity0.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.